Showing posts with label General Knowledge. Show all posts
Showing posts with label General Knowledge. Show all posts

Examples of HLB values according to application needs


• Mixing unlike oils together
– use surfactants with HLB’s of 1 to 3

• Making water-in-oil emulsions
– use surfactants with HLB’s of 4 to 6

• Wetting powders into oils
– use surfactants with HLB’s of 7 to 9

• Making self emulsifying oils
– use surfactants with HLB’s of 7 to 10

• Making oil-in-water emulsions
– use surfactant blends with HLB’s of 8 to16

• Making detergent solutions
– use surfactants with HLB’s of 13 to 15

• For solubilizing oils ( micro-emulsifying ) into water
– use surfactant blends with HLB’s of 13 to 18

Recent advance in Pharma research

Seeds of hope
Hybrid seeds produced at the research labs of Maharashtra Hybrid Seeds Co Ltd. (Mahyco) are not just
contributing enormously to the growth of Indian agricultural sector but also adding to the gene research
capabilities of the country.

Major advance in sleeping sickness drug made by Glasgow scientists.
Scientists have made a key advance in developing a safer cure for sleeping sickness.

Plants could pave the way for new ovarian cancer treatments.
Tropical plants may contain the basis of new and effective treatments for ovarian cancer, according to
researchers at the Universities of Strathclyde and Portsmouth in the UK.

New data for use of Lantus in patients with Type 2 Diabetes.
Sanofi recently announced data that demonstrates that initiating Lantus (insulin glargine [rDNA origin]
injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics (OADs) and dietary changes.

AiCuris’ HCMV Drug Letermovir receives fast track from FDA.
AiCuris announced recently that the US FDA has granted Fast Track designation for one of the company’s lead drugs, AIC246 (INN: Letermovir), an inhibitor of the human cytomegalovirus (HCMV).

-Expresspharma
Courtesy
Mr. Palak Motan
National Institute of Pharmaceutical Education and Research(NIPER)
Ahmedabad

New Product from Roquette

KLEPTOSE® HPB(Hydroxy propy Beta cyclodextrin) excipient grade is suitable for syrups and oral suspensions, as well as for dry formulations. KLEPTOSE® HPB pyrogen-free grade is suitable for parenteral formulations.

PEARLITOL® Flash:A mannitol compound that allies robustness with rapid disintegration. PEARLITOL® Flash offers excellent chemical inertness, needs a minimum of lubricant and makes tablet formulation surprisingly simple. What’s more, it offers the consumer a uniquely pleasing taste experience. Obtained from pea starch.

LYCOAT®:Roquette has developed LYCOAT® range in response to market requirements for more functional coating solutions in terms of organoleptic properties, solubilisation and process efficiency.

NUTRIOSE® - Roquette’s new-generation soluble fiber. Discover its many benefits in nutraceutical and enteral nutrition formulations.

New Excipients by FMC Biolpolymer:

Alubra : Hydrophilic lubricant

It is composed of Sodium Stearyl Fumarat.
Salt of stearic acid is most popular worl wide as lubricant (eg. Mg Stearate) but major problem for lubrication by such stearate is retardation of dissolution due to coating of particles and repels water and avoid wetting.

Fumarate group is added in stearat salt which increase hydrophilicity so dissolution problem will be avoided.

Avicel DG: Dry granulation grade Microcrystalline cellulose

Composed of Dicalcium phosphate and MCC used for roller compaction and dry granulation.
DCP is brittle in nature and MCC is compressible. So Breaking of Brittle DCP increase surface area and lids to Re-compression.

Aptamer : As a therapeutic


What is Aptamer ?
Aptamer is a folded single stranded oligonucleotide that binds to a molecular target  such as a protein.
Aptamers are ssDNA or RNA oligonucleotides with very high affinity for their target.

Example: Ala-Arg-Leu-Hist-Ser-Meth

Mechanism of action : It selectively binds to particular protein or target and renders its activity.
Therapeutically active aptamers inhibit protein-ligand interaction & act as antagonist.

SELEXSystemic Evolution of Ligand by Exponential enrichment
Decide the number of nucleotide base, n
Total types of nucleotide base, 4(A,T,G,C)
4n possible different sequences called nucleic acid library
Immobilize target Protein or Ligand in column.
Pass the different oligonucleotide in column.
Separate the oligonucleotide having highest affinity.


Therapeutic Application
α- Thrombin  
Prevent thrombosis
HIV-1 reverse transcriptase
Inhibit Viral replication
Immunoglobulin E
Prevent Allergy
Vascular Endothelial Growth Factor
Prevent neovascularization
Acetylcholine specific auto antibody
Treat Myasthenia gravis
Platelet derived growth factor
Prevent tumor development


Aseptic Area


  • Ceiling : Smooth surface, easy to clean, Epoxy or vinyl coating
  • Personnel should enter the aseptic area only through an air lock.
  • Material should be transferred through Pass-box sterilizers.
  • Prior filling, area should be sterilized with gaseous disinfectant like formaldehyde.
  • Surface should be sterilized using UV lamp.
  • HEPA (High efficiency Particulate Air Filter: 99.97 % efficiency, 0.3mcM or larger particles must be retained) filter should be placed in order to control particles.
  • Air handling unit (AHU) to control temperature and humidity.
  • Laminar Air Flow: 90 +- 20 ft/min with parallel flow.
  • DOP test: Dioctylphalate smoke used to measure efficiency of HEPA filter by anemometer.

Pharmacy in Aerospace

  • Aerospace medicine provides a unique twist on traditional medicine.
  • A subspecialty for physicians exists to care for the altered body systems as a result of extreme environments.
  • Pharmacy practice has expanded to accommodate specialized medicine through pharmacy residencies.
  • No formal training in aerospace medicine currently exists for pharmacists.
  • Time and resources are committed behind the scenes that require an understanding of pharmaceutical science and an understanding of all the aspects of flight.
  • NOMI, Brooks, NASA, and virtually every country represented in AsMAhas some form of a Pharmacy and Therapeutics committee to determine not only safe use of drugs in aerospace for physical ailments, but also performance “management.”
  • An understanding of the changes to the body and body systems as it relates to pharmacy is necessary by the profession.
  • Providing an Aerospace Pharmacy residency would accomplish this task and allow pharmacists to provide better care for aerospace and space travelers in both government and civilian programs.
Pharmacy practice areas embedded within aerospace medicine are identified.

Deficits in current pharmacy curriculum identified
–Physiological changes to body in microgravity
–Changes to pharmacokinetics and pharmacodynamics
–Pharmaceutics issues
   •Fluid properties in zero G
–Drug delivery systems
–Interpretation of pharmacy law

Aerospace Physiologic Changes Not Addressed in Current Pharmacy School Curriculum

•Pathophysiologyof the body (Patient Care, Pharmacovigilance, DI, Commercial Space Travel)
Understanding of all altered body systems important for pharmacist to understand in order to provide best treatment options
–Altered blood volume –pharmacokinetics?
–Altered hepatic/renal fxn–therapeutics?
•Biodynamicsof acceleration
•Aerospace otolaryngology
•Aerospace ophthalmology
•Aerospace cardiology
•Aerospace neurology
•Aerospace nephrology
•Radiation biology
–Effects on body, what about drugs?

Doctor of Pharmacy

In the USA, legal requirements to becoming a pharmacist include graduating with a Doctor of Pharmacy (PharmD) degree from an accredited college of pharmacy, serving an internship under a licensed pharmacist, and passing a state (NAPLEX) and law exam. The designation PharmD is often likened to a PhD degree, however in actuality it is an advanced degree that became the standard of practice for graduates of pharmacy schools around the turn of the 21st century (2001). The former degree was a Bachelor of Pharmacy and required slightly less schooling and different curriculum. Due to the changes to health care in today's society and the increasing need for counseling and medication maintenance, pharmacists have taken on a larger role as clinicians. This increase in the need for accessible health care information for consumers has led to great strides in the field of pharmacy. One result of this has been a change in the way pharmacy schools structure their curriculum as well as an advanced doctorate degree, which further sets the pharmacist apart as a trusted ally in a patient's health care treatment regimen. In fact, pharmacists consistently rank as one of the most trusted professionals in today's society. This degree requires the completion of at least five years of post-secondary schooling but usually requires at least 6-8 years at present time, depending on which state you live in and the pharmacy school which you attend. The former degree obtained upon completion of pharmacy school was a Bachelors in Pharmacy or BS and pharmacists with this designation were given the title RPh. In the USA, pharmacist who acquire a PharmD degree are legally allowed to add the prefix "Dr." before his / her name. Pharmacy is the health profession that links the health sciences with the chemical sciences and it is charged with ensuring the safe and effective use of pharmaceutical drugs.

INDIA
The Pharmacy Council of India permitted a few universities to start Pharm.D (post baccalaureate)(2 years + 1 full working year internship in a 300 bedded hospital)for B.Pharm graduates. The first batch of Pharm.D students will graduate by 2011. The government has taken new innovative steps for increasing the interest of the students. By 2014 there will be more colleges offering Pharm.D courses in India.

United States

In the United States, the PharmD. (Doctor of Pharmacy) degree is a professional degree that prepares the graduate for pharmacy practice. It is awarded after four years of pharmacy school, including one year of practice experience. Most states require students to take an entry test (PCAT) and complete 60-90 credit hours (2–3 years) of university coursework in the sciences, mathematics, composition and humanities before entry into a professional program. Many pharmacy students complete a bachelors degree before entry to pharmacy school.
Total time: 2–4 years undergraduate (Associate or Bachelor degree), 4 years professional (PharmD), optional 1–3 years of specialization (residency/fellowship).
Previously, in the United States, the bachelor's degree in pharmacy was the first-professional degree for pharmacy practice. Some schools and colleges of pharmacy offered a post-baccalaureate graduate PharmD degree. These graduate level degrees became prevalent in US programs in the late 1960s.
In 1990, the American Association of Colleges of Pharmacy (AACP) mandated that a doctor of pharmacy degree would be the new first-professional degree. Currently all accredited schools and colleges of pharmacy in the US offer the PharmD degree. Many also offer post-PharmD graduate programs in specialized areas of the profession.
The current PharmD degree curriculum is very different than that of the prior BS in pharmacy and now includes extensive didactic clinical preparation and a full year of hands-on practice experience.


Canada

In Canada the PharmD program is offered in both English and French. Currently in Canada PharmB (and not PharmD) is the minimum level to practice pharmacy. Students enrolled in the program must have graduated from a CCAPP (Canadian Council for Accreditation of Pharmacy Programs) or an ACPE (Accreditation Council for Pharmacy Education) school with an accredited teaching program or must have passed the PEBC (Pharmacy Examining Board of Canada) Evaluating and Qualifying examinations. As of fall 2007, the PharmD program is offered at the Université de Montréal(in French) and is the first Canadian university to give this program instead of the baccalaureate program in pharmacy. The PharmD program was offered as a graduate program. In Canada, pharmacist who acquire a Pharm.D degree aren't legally allowed to add the prefix "Dr." before his / her name. Pharmacy is the health profession that links the health sciences with the chemical sciences and it is charged with ensuring the safe and effective use of pharmaceutical drugs.

High-performance liquid chromatography


High-performance liquid chromatography (sometimes referred to as high-pressure liquid chromatography), HPLC, is a chromatographic technique that can separate a mixture of compounds and is used in biochemistry and analytical chemistry to identify, quantify and purify the individual components of the mixture.
HPLC typically utilizes different types of stationary phases, a pump that moves the mobile phase(s) and analyte through the column, and a detector to provide a characteristic retention time for the analyte. The detector may also provide additional information related to the analyte, (i.e. UV/Visspectroscopic data for analyte if so equipped). Analyte retention time varies depending on the strength of its interactions with the stationary phase, the ratio/composition of solvent(s) used, and the flow rate of the mobile phase. It is a form of liquid chromatography that utilizes smaller column size, smaller media inside the column, and higher mobile phase pressures.
With HPLC, a pump (rather than gravity) provides the higher pressure required to move the mobile phase and analyte through the densely packed column. The increased density arises from smaller particle sizes. This allows for a better separation on columns of shorter length when compared to ordinary column chromatography.


Operation

The sample to be analyzed is introduced, in small volumes, into the stream of mobile phase. The solution moved through the column is slowed by specific chemical or physical interactions with the stationary phase present within the column. The velocity of the solution depends on the nature of the sample and on the compositions of the stationary (column) phase. The time at which a specific sample elutes (comes out of the end of the column) is called the retention time; the retention time under particular conditions is considered an identifying characteristic of a given sample. The use of smaller particle size column packing (which creates higher back pressure) increases the linear velocity giving the components less time to diffuse within the column, improving the chromatogram resolution. Common solvents used include any miscible combination of water or various organic liquids (the most common are methanol and acetonitrile). Water may contain buffers or salts to assist in the separation of the sample components, or compounds such as trifluoroacetic acid which acts as an ion pairing agent.
A further refinement of HPLC is to vary the mobile phase composition during the analysis; gradient elution. A normal gradient for reversed phase chromatography might start at 5% methanol and progress linearly to 50% methanol over 25 minutes; the gradient depends on how hydrophobic the sample is. The gradient separates the sample mixtures as a function of the affinity. This partitioning process is similar to that which occurs during a liquid-liquid extraction but is continuous, not step-wise. In this example, using a water/methanol gradient, more hydrophobic components will elute(come off the column) when the mobile phase consists mostly of methanol (giving a relatively hydrophobic mobile phase).
The choice of solvents, additives and gradient depend on the nature of the column and sample. Often a series of tests are performed on the sample together with a number of trial runs in order to find the HPLC method which gives the best peak separation.

Countercurrent chromatography (CCC)

Countercurrent chromatography (CCC) is the form of liquid-liquid chromatography in which, centrifugal or gravitational force is employed to maintain a bed of one liquid phase in a coil or train of chambers, in the absence porous supporting matrix, while a stream of second immiscible phase is pumped through the system in contact with the stationary phase.

  • One liquid is held as stationary phase
  • The SP retains 40-90% of the total volume of column
  • The liq. SP is stable as long as the gravitational/centrifugal force exists
  • The advantages of having liquid SP are
    • High loading capacity
    • Very simple solute retention mechanism
    • Either phase can be used as mobile phase
    • No pH problem
  • Other is pumped through it with good retention of SP
  • A series of simultaneous Mixing and Settling zones occur in the column


Practical modifications to the PCR technique to increase specificity

Hot-start PCR:
Hot-start PCR is a technique that reduces non-specific priming that occurs during the preparation of the reaction components. The technique may be performed manually by simply heating the reaction components briefly at the melting temperature (e.g., 95˚C) before adding the polymerase.

Touchdown PCR:
Touchdown PCR is a variant of PCR that reduces nonspecific primer annealing by gradually lowering the annealing temperature as PCR cycling progresses. The annealing temperature at the initial cycles is usually a few degrees above the Tm of the primers used, while at the later cycles, it is a few degrees below the primer Tm . The higher temperatures give greater specificity for primer binding, and the lower temperatures permit more efficient amplification from the specific products formed during the initial cycles.

Nested PCR:
Makes use of nested primers i.e. Two sets of primers are being used in two successive PCR reactions. In the first reaction, one pair of primers is used to generate DNA products, which act as templates for the second set of primers whose binding sites are within the intended DNA target.
It increase the specificity and reduces background due to non-specific amplification of DNA. However it requires more detailed knowledge of the target sequences.



Can RNA be PCR amplified ?
Yes, but not directly
Reverse Transcriptase PCR – RT PCR

A method to amplify cDNA copies of RNA (whole or mRNA).
A sensitive and versatile technique that can be used to,
Retrieve and clone the 5’ and 3’ termini of mRNAs
Generate large cDNA libraries from very small amounts of mRNA.
Identify mutations and polymorphisms in transcribed sequences.
Measure strength of gene expression when amount of mRNA is limited.


Steps in RT-PCR
RNA isolation
Conversion to cDNA template using reverse transcriptase (first strand synthesis) and oligo dT primers
RNA digested from the hybrid using RNaseH
cDNA amplified using DNA polymerase and DNA oligo primers (second strand synthesis)

Reverse Transcriptases:
Mesophilic enzymes encoded by Avian myeloblastosis virus (AMV) and the Moloney strain of Murine leukemia virus (Mo-MLV)
Tth DNA polymerase


Real Time PCR

PCR is an exponential process, small differences in efficiency at each cycle can lead to large differences in yield of the amplified product.

Problem occurs when we need to quantitate differences in mRNA levels

Although the traditional methods of quantitating mRNA are fairly good such as northern blotting and in situ hybridization, they do not approach the ease and speed of Real Time PCR.

Real Time PCR also has a much wider dynamic range of up to 107-fold (compared to 1000-fold in conventional RT-PCR). The dynamic range of an assay determines how much the target concentration can vary and yet still be quantified. This wide dynamic range also results in a more accurate quantitation.


PCR-ELISA

PCR-ELISAs are a capture assay for nucleic acids that mimic enzyme linked immunosorbent assays.  In this assay, PCR products hybridized to an immobilized capture probe.  The assay thus measures sequences internal to the PCR product and is a less expensive assay and an alternative to real time PCR. PCR ELISAs are useful for detecting and differentiating between multiple targets.


Multiplex-PCR:
The use of multiple, unique primer sets within a single PCR reaction to produce amplicons of varying sizes specific to different DNA sequences.

By targeting multiple genes at once, additional information may be gained from a single test run that otherwise would require several times the reagents and more time to perform.

Annealing temperatures for each of the primer sets must be optimized to work correctly within a single reaction, and amplicon sizes, i.e., their base pair length, should be different enough to form distinct bands when visualized by gel electrophoresis.

Applications of PCR

a)Generation of probes
b)Generation of cDNA libraries
c)Production of DNA for sequencing
d)Analysis of mutations
e)Diagnosis of monogenic diseases (single gene disorders)
f)PCR use in Pre-implantation Genetic Diagnosis (PGD).
g)PCR in forensic science
h)Site-directed Mutagenesis
i)Comparison of gene expression
j)Rapid characterization of DNAs cloned in prokaryotic vectors
k)Cloning novel members of protein families using homology PCR
l)Detection of bacteria and viruses

Polymerase Chain Reaction (PCR)

Definition:
Amplification means making multiple identical copies (replicates) of a DNA sequence. This can be carried out by various methods, that include in vivo amplification including cell cloning where host cells (manipulated using a vector to contain a DNA insert of interest) are allowed to divide and, as they do so, the insert is replicated.


Historical background…



  • Method first proposed by H. G. Khorana & colleagues in 1970’s.
  • 15 years later the idea was independently conceived by Karry Mullis in 1983.
  • Used the Klenow fragment of E. coli DNA polymerase to describe the in-vitro amplification of genes.
  • Saiki et al in 1988 used the thermostable DNA polymerase from Thermus aquaticus and greatly increased the efficiency of PCR.
  • In 1989, Science magazine selected PCR as the major scientific development and Taq DNA polymerase as the molecule of the year.
  • Karry Mullis was awarded the Noble price for chemistry in 1993.
Seven essential components required
  1. Template DNA
  2. A thermostable DNA polymerase
  3. A pair of synthetic oligonucleotide primers.
  4. Divalent cations (Mg 2+ )
  5. dNTPs
  6. Buffer to maintain pH ( Tris-Cl pH 8.3 – 8.8)
  7. Monovalent cations

    The PCR usually consists of a series of 30 to 35 cycles. Most commonly, PCR is carried out in three steps, often preceded by one temperature hold at the start and followed by one hold at the end. A typical PCR cycle has following steps


ØDenaturation (94-95°C, for ~ 30 s)
The template is denatured by heat

ØAnnealing (55-60°C, for ~ 30 s)
Annealing of oligonucleotide primers to single stranded       target sequences

ØElongation (72°C)
Extension of annealed primers by a thermostable  polymerase

Cell based assay for Drug discovery.

Pharmaceutical companies approach drug discovery in a variety of ways. An early part of the experimental process often involves screening a large number of compounds using defined biochemical assays in an ultrahigh-throughput format.

However, the effect of a drug on an organism is complex and involves interactions at multiple levels that cannot be predicted using biochemical assays. Trying to understand this complexity has contributed to an increased use of cell-based screening assays as more biologically relevant surrogates to predict the response of the organism. In addition, at some point in the drug discovery process, predicting cellular toxicity is important. 

Eukaryotic cell culture is accepted as the model system of choice to get a first approximation of toxicity. Furthermore, advances in assay chemistries and signal detection technology have allowed miniaturization of cell-based assays, making it more convenient to perform dose-response experiments during primary screens.


(1) ATP Assay of Cell Viability
The amount of ATP in cells correlates with cell viability. Within minutes after loss of membrane integrity, cells lose the ability to synthesize ATP; endogenous ATPases destroy any remaining ATP, and ATP levels fall precipitously. The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous method to determine the number of viable cells in culture. Detection is based on using the luciferase reaction to measure the amount of ATP from viable cells. The CellTiter-Glo® Reagent does three things upon addition to cells. It lyses cell membranes to release ATP; it inhibits endogenous ATPases, and it provides luciferin and luciferase necessary to measure ATP using a bioluminescent reaction. The “glow-type” signal of the proprietary Ultra-Glo™ Luciferase can be recorded with a luminometer, CCD camera or modified fluorometer and generally has a halflife of five hours, providing a consistent signal across large batches of plates.

The CellTiter-Glo® Assay can detect as few as 15 cells  Although equilibration of assay plates to room temperature is recommended before performing the assay, the assay can be completed rapidly. The luminescent signal can be detected as soon as 10 minutes after adding reagent or several hours later for batch processing of plates. Among the homogeneous viability assays, the ATP assay is the fastest to perform and can detect the smallest number of cells, making it useful for 384- and 1,536-well formats.

(2) Tetrazolium Reduction Cell Viability Assay
The CellTiter 96® AQueous One Solution Cell Proliferation Assay is the industry standard for homogeneous colorimetric cell viability assays. Viable cells convert the MTS tetrazolium reagent into a colored formazan product during a 1- to 4-hour incubation. The amount colored formazan product is directly proportional to the number of viable cells.

(3) Resazurin Reduction Cell Viability Assay
The CellTiter-Blue® Cell Viability Assay uses an optimized reagent containing resazurin, which is reduced to fluorescent resorufin in living cells. The reagent is added directly to cells in culture, incubated, and the signal is read using a multiwell fluorometer. Because different cell types have different abilities to reduce resazurin, optimizing incubation time with the CellTiter-Blue® Reagent can improve assay sensitivity for a given model system. The detection sensitivity is intermediate between the ATP assay and the MTS reduction assay. The simple, inexpensive procedure can be multiplexed with other assays to collect a variety of data. The assay provides good Z´-factor values in HTS situations as well.


(4) LDH-Release Cytotoxicity Assay
Cells that have lost membrane integrity release lactate dehydrogenase (LDH) into the surrounding medium. The CytoTox-ONE™ Homogeneous Membrane Integrity Assay is a fluorescent method that uses coupled enzymatic reactions to measure the release of LDH from damaged cells as an indicator of cytotoxicity. The assay is designed to estimate the number of nonviable cells present in a mixed population of living and dead cells. Alternatively, if a cell lysis reagent is used, the same assay chemistry can be used to determine the total number of cells in a population. The CytoTox-ONE™ Reagent does not damage living cells, and the assay can be performed directly in cell culture using a homogeneous method. The CytoTox-ONE™ Assay is fast, typically requiring only a 10-minute incubation period, and is compatible with 96- and 384-well formats. The detection sensitivity is a few hundred cells but can be limited by the LDH activity present in serum used to supplement culture medium. When automated on the Biomek® 2000 workstation, the CytoTox-ONE™ Assay gave excellent Z´-factor values.


(5) Fluorescent Caspase-3/7 Assay to Detect Apoptosis
The activity of executioner caspases such as caspase-3 and -7 is an accepted, reliable indicator of apoptosis. The Apo-ONE® Homogeneous Caspase-3/7 Assay detects caspase-3/7 activity based on the cleavage of a profluorescent DEVD peptiderhodamine 110 substrate. The Apo-ONE® Reagent is prepared by combining buffer and substrate and adding it directly to culture wells using a 1:1 ratio of reagent to medium, mixing and incubating. The reagent permeabilizes the cells to release the caspase, delivers the profluorescent substrate, and provides optimized conditions to stabilize caspase activity. Because the fluorescent R110 product continues to accumulate in the presence of active caspase-3 and -7, extending the incubation period up to 18 hours increases the signal-tobackground ratio, providing greater sensitivity. The Apo-ONE® Assay is easily scalable for HTS as long as the 1:1 ratio of reagent to medium is maintained. The detection sensitivity is in the range of several hundreds of cells but can be influenced by the length of incubation.


(6) Luminescent Caspase Assays to Detect Apoptosis
The Caspase-Glo® 3/7, 8 and 9 Assays measure caspase activity based on the cleavage of a peptide-aminoluciferin substrate. Caspase cleavage of the substrate liberates free aminoluciferin, which can be used as a substrate by luciferase to generate light. The Caspase-Glo® Reagent is prepared by combining a lyophilized substrate and buffer. The reagent is added directly to cells in culture at a 1:1 ratio of reagent to medium, mixed and incubated, and luminescence is recorded. The assay has a flexible incubation time for recording the “glow-type” luminescent signal. When steady state is reached after approximately 30 minutes to one hour of incubation, the luminescent signal of this coupled enzymatic assay is directly proportional to the amount of caspase over a broad linear range. The Caspase-Glo® Assays are the most sensitive caspase assays available. Because they are luminescent assays, fluorescent compounds will not interfere with results.



Radioimmunoassay (RIA)


Radioimmunoassay (RIA) is a very sensitive technique used to measure concentrations of antigens (for example, hormonelevels in the blood) by use of antibodies. As such, it can be seen as the inverse of a radiobinding assay, which quantifies an antibody by use of corresponding antigens.
Although the RIA technique is extremely sensitive and extremely specific, requiring specialized equipment, it remains the least expensive method to perform such tests. It requires special precautions and licensing, since radioactive substances are used. Today it has been supplanted by the ELISA method, where the antigen-antibody reaction is measured using colorimetric signals instead of a radioactive signal. However, because of its robustness, consistent results and low price per test , RIA methods are again becoming popular. It is generally more simple to perform than a bioassay.
To perform a radioimmunoassay, a known quantity of an antigen is made radioactive, frequently by labeling it with gamma-radioactive isotopes of iodine attached to tyrosine. This radiolabeled antigen is then mixed with a known amount of antibody for that antigen, and as a result, the two chemically bind to one another. Then, a sample of serum from a patient containing an unknown quantity of that same antigen is added. This causes the unlabeled (or "cold") antigen from the serum to compete with the radiolabeled antigen ("hot") for antibody binding sites. As the concentration of "cold" antigen is increased, more of it binds to the antibody, displacing the radiolabeled variant, and reducing the ratio of antibody-bound radiolabeled antigen to free radiolabeled antigen. The bound antigens are then separated from the unbound ones, and the radioactivity of the free antigen remaining in the supernatant is measured using a gamma counter. Using known standards, a binding curve can then be generated which allows the amount of antigen in the patient's serum to be derived.

MTT Assay for Cell Viability

The MTT assay and the MTS assay are colorimetric assays for measuring the activity of enzymes that reduce MTT or close dyes (XTT, MTS, WSTs) toformazan dyes, giving a purple color. A main application allows to assess the viability (cell counting) and the proliferation of cells (cell culture assays). It can also be used to determine cytotoxicity of potential medicinal agents and toxic materials, since those agents would stimulate or inhibit cell viability and growth.



MTT and related tetrazolium salts

MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), is reduced to purple formazan in living cells. A solubilization solution (usually either dimethyl sulfoxide, an acidified ethanol solution, or a solution of the detergent sodium dodecyl sulfatein diluted hydrochloric acid) is added to dissolve the insoluble purple formazan product into a colored solution. The absorbance of this colored solution can be quantified by measuring at a certain wavelength (usually between 500 and 600 nm) by a spectrophotometer. The absorption maximum is dependent on the solvent employed.
XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) has been proposed to replace MTT, yielding higher sensitivity and a higher dynamic range. The formed formazan dye is water soluble, avoiding a final solubilization step.
Water soluble tetrazolium salts are more recent alternatives to MTT: they were developed by introducing positive or negative charges and hydroxy groups to the phenyl ring of the tetrazolium salt, or better with sulfonate groups added directly or indirectly to the phenyl ring.
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), in the presence of phenazine methosulfate (PMS), produces a formazan product that has an absorbance maximum at 490-500 nm in phosphate-buffered saline.
WSTs (Water soluble Tetrazolium salts) are a series of other water soluble dyes for MTT Assays, developed to give different absorption spectra of the formed formazans.WST-1 and in particular WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium), are advantageous over MTT in that they are reduced outside cells, combined with PMS electron mediator, and yield a water-soluble formazan. Finally, WST assays (1) can be read directly (unlike MTT that needs a solubilization step), (2) give a more effective signal than MTT, and (3) decrease toxicity to cells (unlike cell-permeable MTT, and its insoluble formazan that accumulate inside cells).

MTT Assays significance

These reductions take place only when reductase enzymes are active, and therefore conversion is often used as a measure of viable (living) cells. However, it is important to keep in mind that other viability tests (such as the CASY cell counting technology) sometimes give completely different results, as many different conditions can increase or decrease metabolic activity. Changes in metabolic activity can give large changes in MTT or MTS results while the number of viable cells is constant. When the amount of purple formazan produced by cells treated with an agent is compared with the amount of formazan produced by untreated control cells, the effectiveness of the agent in causing death, or changing metabolism of cells, can be deduced through the production of a dose-response curve.

National Institute of Pharmaceutical Education and Research,India

The National Institute of Pharmaceutical Education and Research, India was established by the Government of India to cater to the long-standing demand for setting up a dedicated nodal for quality higher education and advanced research in the pharmaceutical sciences. Colonial rule in an era of rapid advancement of sciences and technology had left the once a land of pioneers in sciences a few decades behind the frontline researchers. On the lines of similar initiatives in engineering/technology (the Indian Institutes of TechnologyIndian Institute of ScienceNational Institutes of Technology), medicine (AIIMS), and management (Indian Institutes of Management), the policy makers made a humble start in the field of pharmaceuticals.


The main objective of NIPER is to provide leadership in pharmceutical science with industry, national and international collaborations and promoting community and institutional pharmacy apart from establishing national centres in advanced research and emerging areas.

GlaxoSmithKline

1715
Plough Court pharmacy, the forerunner of Allen and Hanburys Ltd, is established in London by Silvanus Bevan.


1830
John K Smith opens his first drugstore in Philadelphia. John's younger brother, George, joins him in 1841 to form John K Smith & Co. 


1842
Thomas Beecham launches the Beecham's Pills laxative business in England. The laxative is to become widely successful. 


1859

Beecham opens the world's first factory to be built solely for making medicines at St Helens in England. 
1865
Mahlon Kline joins Smith and Shoemaker - as John K Smith and Co had become - as a bookkeeper 
1873
Joseph Nathan, who left the UK to seek new business opportunities 20 years before, establishes a general trading company at Wellington in New Zealand - Joseph Nathan and Co - the foundation for the Glaxo company to be formed later. 
1875
Mahlon Kline took on additional responsibilities as a salesman and added many new and large accounts. He is rewarded when the company, Mahlon K Smith and Company, is renamed Smith, Kline and Company. 
1880
Burroughs Wellcome & Company is established in London by American pharmacists Henry Wellcome and Silas Burroughs, four years after Joseph Nathan opened a London office. 
1884
Tabloid is registered as a Burroughs Wellcome and Company trademark to describe its compressed tablets 
1885
Thomas Beecham's company acquires headquarters on the corner of Silver Street and Water Street, St Helens, England. Two years later, the company's new factory in St Helens becomes the first in the area to have electricity 
1891
Smith, Kline and Company acquires French, Richards and Company, providing a greater portfolio of consumer brands 

1891

The Wellcome Tropical Research Laboratories open 
1904
 
Nathan starts dried milk powder production in New Zealand, exporting to London. Henry Wellcome hires Henry Dale, who is to discover and study, among other things, histamine and how nerve impulses are transmitted.
1906
Glaxo is registered by Joseph Nathan and Co as a trademark for dried milk. A Burroughs Wellcome subsidiary is created in New York. 
1908
The Glaxo department of Joseph Nathan and Co opens in London and the first "baby book" is published. 
1910
The "Blue Line" is added to the Smith, Kline and French name, a range including poison ivy lotion, iron tablets and lozenges 
1913
 
Production of Beecham's Pills laxative reaches one million a day.
1919
 
Alex C Maclean establishes Macleans Ltd, manufacturing own-name products for chemists. Mahlon Kline begins the novel practice of sending pharmaceutical samples through the mail to doctors across the US.
1924
The vitamin D preparation Ostelin becomes Glaxo's first pharmaceutical product. The Wellcome Foundation Ltd is formed. The Beecham estate is purchased by Philip Hill, who realised that the Beecham's Pills business could, through diversification, become the basis of a major company. 
1926
Beecham's Powders cold remedy is introduced 
1929
 
Smith, Kline and French Company is renamed Smith Kline and French Laboratories and becomes more focused on research. 
1930
 
Sydney Smith of Wellcome isolates the glycosides of Digitalis lanata, a variety of foxglove. Lanoxin (digoxin) is used in the treatment of heart failure. 
1935
 
Glaxo Laboratories is formed and new facilities are created at Greenford, near London. 
1936
 
Sir Henry Wellcome's will leaves sole ownership of The Wellcome Foundation Ltd to a UK medical research charity, today called the Wellcome Trust. Sir Henry Dale of Wellcome is awarded the Nobel Prize for Medicine for his work in the chemical transmission of nerve impulses 
1938
Beecham acquires Macleans Ltd and Eno's Proprietaries Ltd. Macleanstoothpaste and Lucozade energy-replacement drink are added to Beecham's product line 
1939
 
Beecham acquires County Perfumery Co Ltd, manufacturers of Brylcreem, a men's hair application. 
1943
Beecham Research Laboratories is formed with the mission to focus exclusively on basic pharmaceutical research. 
1945
 
Beecham Group Ltd is established, replacing Beecham Pills Ltd and Beecham Estates Ltd - later known as Beecham Group plc - and incorporates Beecham Research Laboratories. 
1947
Glaxo Laboratories Ltd absorbs the Joseph Nathan company and becomes the parent company. Glaxo is listed on the London Stock Exchange. New Beecham laboratories are established at Brockham Park in Surrey, England. 
1948
 
Vitamin B12 is isolated by Glaxo scientists for the treatment of pernicious anaemia. Streptomycin for TB treatment is produced by Glaxo scientists. Polymixin anti-bacterials are developed by Wellcome. Smith Kline and French Laboratories acquire a new site at 1530 Spring Garden Street, Philadelphia. 
1949
 
Beecham Group Ltd acquires C L Bencard Ltd, a company specialising in allergy vaccines. It is a first step towards ethical products for the Beecham company. 
1950s
Thorazine (chlorpromazine), an anti-psychotic from Smith Kline and French, is introduced. The product will revolutionise the treatment of mental illness during the 1950s and become the product of reference in the first generation of central nervous system drugs. 
1952
Smith Kline and French introduces the first time-released medicine, Dexedrine (dextroamphetamine sulfate). It is marketed and used in a Spansule - a novel form of drug delivery. Daraprim (pyrimethamine) anti-malarial is developed by Wellcome. 
1953
Wellcome launches its antileukaemic drug Purinethol (mercaptopurine). 
1958
 
Glaxo acquires Allen and Hanburys Ltd. 
1959
 
The Wellcome Foundation acquires Cooper, McDougall and Robertson Ltd, an animal health company founded in 1843. 
1958-1959
 
Wellcome launches range of Actifed antihistamine products for head colds and allergies. 
1960
Smith Kline and French launches Contac, the cold remedy, using the Spansule to release an initial major therapeutic dose, followed by numerous smaller doses, over 10-12 hours. The company moves into the animal health business with the acquisition of Norden Laboratories. 
1963
 
Betnovate (betamethasone) becomes the first of Glaxo's range of steroid skin disease treatments. In the mid-1960s, Smith Kline and French acquires RIT (Recherche et Industrie Therapeutiques), a vaccines business. 
1968
Septrin (co-trimoxazole) anti-bacterial from Wellcome is introduced. 
1969
Glaxo launches Ventolin (salbutamol) for asthma, developed at Ware and marketed under the Allen and Hanburys name. Ceporex, Glaxo's first oral cephalosporin antibiotic, is introduced. Smith Kline and French enters the clinical laboratories business through the purchase of seven laboratories in the US and one in Canada. 
1970
 
Burroughs Wellcome Inc moves its production facility from New York to Greenville, North Carolina. 
1971
 
Wellcome launches its rubella vaccine. Burroughs Wellcome Inc opens its research site at Research Triangle Park, North Carolina. 
1972
Scientists at Beecham Research Laboratories discover amoxicillin and launch Amoxil, to become a widely-used antibiotic. Beecham Group plc is unsuccessful in its bid for Glaxo Group Ltd - and Glaxo is unsuccessful in its attempt to merge with UK chemists Boots. Inhaled steroid beclomethasone dipropionate is launched by Glaxo as Becotide (beclomethasone dipropionate) for asthma, followed in 1975 by Beconase for rhinitis conditions. 
1976
The H2 blocker Tagamet (cimetidine) is introduced in the UK by the SmithKline Corporation, and in the US in the following year. The treatment will revolutionise peptic ulcer therapy. 
1978
 
Through the acquisition of Meyer Laboratories Inc, Glaxo's business in the US is started, to become Glaxo Inc from 1980. The broad-spectrum injectable antibiotic Zinacef (cefuroxime) is introduced by Glaxo. 
1981
The anti-ulcer treatment Zantac (ranitidine) is launched by Glaxo and is to become the world's top-selling medicine by 1986. Augmentin (amoxicillin / clavulanate potassium), to combat a wide range of bacterial infections in children and adults, is launched by Beecham. The antiviral Zovirax (aciclovir) is launched by Wellcome for herpes infections 
1982
 
SmithKline acquires Allergan, an eye and skincare business, and merges with Beckman Instruments Inc, a company specialising in diagnostics and measurement instruments and supplies. The company is renamed SmithKline Beckman. John Vane of the Wellcome Research Laboratories is awarded the Nobel Prize, with two other scientists, "for their discoveries concerning prostaglandins and related biologically active substances." 
1983
 
Glaxo Inc moves to new facilities in Research Triangle Park and Zebulon, North Carolina. The broad-spectrum injectable antibiotic Fortum (ceftazidime) is launched. Wellcome launches Flolan (epoprostenol) for use in renal dialysis. 
1986
Beecham acquires the US firm Norcliff Thayer, adding Tums antacid tablets and Oxy skin care to its portfolio. 
1987
 
The AIDS treatment Retrovir (zidovudine) is launched by Wellcome. Glaxo introduces the oral antibiotic Zinnat (cefuroxime axetil). 
1988
 
SmithKline BioScience Laboratories acquires one of its largest competitors, International Clinical Laboratories, Inc, increasing the company's size by half and establishing SmithKline BioScience Laboratories as the industry leader. The Nobel Prize for medicine is awarded to George Hitchings and Gertrude Elion, of Burroughs Wellcome Inc, and to Sir James Black, who had worked at the Wellcome Foundation and Smith Kline and French Laboratories, "for their discoveries of important principles for drug treatment." 
1989
SmithKline Beckman and The Beecham Group plc merge to form SmithKline Beecham plc. Engerix-B hepatitis B vaccine (recombinant), a genetically engineered hepatitis B vaccine, is launched in the US and France. 
1990
The synthetic lung surfactant Exosurf and the anti-epileptic drug Lamictal (lamotrigine) are launched by Wellcome. Glaxo introduces long-actingSerevent (salmeterol) for asthma, the inhaled corticosteroid Flixotide(fluticasone propionate) and Zofran (ondansetron) anti-emetic for cancer patients. 
1991
 
Glaxo launches its novel treatment for migraine, Imigran (sumatriptan),Lacipil (lacidipine) for high blood pressure, and Cutivate (fluticasone propionate) in the US for skin diseases. SmithKline Beecham moves its global headquarters to New Horizons Court at Brentford, England. SmithKline Beecham's Seroxat/Paxil (paroxetine hydrochloride) is launched in the UK, its first market. 
1992
 
Mepron (atovaquone) for AIDS-related pneumonia is introduced by Burroughs Wellcome in the US. SmithKline Beecham's Havrix hepatitis A vaccine, inactivated, the world's first hepatitis A vaccine, is launched in six European markets. 
1993
SmithKline Beecham and Human Genome Science negotiate a multi-million-dollar research collaboration agreement for identifying and describing the functions of the genes in the human body. Glaxo introduces Flixotide(fluticasone propionate) for bronchial conditions. 
1994
SmithKline Beecham purchases Diversified Pharmaceutical Services, Inc, a pharmaceutical benefits manager. Sterling Health also is acquired, making SmithKline Beecham the third-largest over-the-counter medicines company in the world and number one in Europe and the international markets. With the intention of focusing on human healthcare, SmithKline Beecham sells its animal health business. 
1995
 
Glaxo and Wellcome merge to form Glaxo Wellcome. Glaxo Wellcome acquires California-based Affymax, a leader in the field of combinatorial chemistry. The Queen opens Glaxo Wellcome's Medicines Research Centre at Stevenage in England. Valtrex (valaciclovir) is launched by Glaxo Wellcome as an anti-herpes successor to Zovirax (acyclovir). SmithKline Beecham acquires Sterling Winthrop's site in Upper Providence, Pennsylvania, to fulfil US R&D expansion needs. 
1996
 
Community Partnership is established by SmithKline Beecham to focus philanthropy on community-based healthcare. SmithKline Beecham Healthcare Services is formed by combining the clinical laboratories, disease management and Diversified Pharmaceutical Services businesses. 
1997
 
SmithKline Beecham's research centre, New Frontiers Science Park, opens at Harlow in England. SmithKline Beecham and Incyte Pharmaceuticals create a joint venture - diaDexus - to discover and market novel molecular diagnostics based on the use of genomics. 
1998
 
SmithKline Beecham and the World Health Organization announce a collaboration to eliminate lymphatic filariasis (elephantiasis) by the year 2020. The largest pharmaceutical company in Poland is created with the acquisition of Polfa Poznan by Glaxo Wellcome. 
1999
 
The 30th anniversary of the launch of Ventolin (albuterol) is marked as respiratory becomes Glaxo Wellcome's largest therapeutic area. Sharpening its focus on pharmaceuticals and consumer healthcare, SmithKline Beecham divests SmithKline Beecham Clinical Laboratories and Diversified Pharmaceutical Services. SmithKline Beecham's Avandia (rosiglitazone maleate), for the treatment of type 2 diabetes, is launched in the US. 
2000
 
GlaxoSmithKline is formed through the merger of Glaxo Wellcome and SmithKline Beecham. 

Avandia passes one million retail prescriptions in the US. 

GSK makes a ground-breaking pledge to provide three HIV/AIDS medicines to developing country governments at significant price reductions. 
2001
 
GSK moves to its new UK headquarters in Brentford, West London. GSK House consists of four, five-storey buildings and a 16-storey tower block linked by an internal fully-glazed 'street'. The building was designed with input from employees. 

Twinrix, the first combination vaccine to prevent hepatitis A and B is approved by the FDA. 

GSK reorganises its research and development efforts into Centres of Excellence for Drug Development (CEDDs), small business units that emphasise flexibility, innovation and therapeutic focus. 

GSK launches Advair, an anti-asthma medicine, in the US and acquires theSensodyne range of oral care products. 

GSK launches the African Malaria Partnership to help combat a disease that kills more than one million people every year.
2002
 
Avandia reaches 20 million prescriptions milestone in the US. 

GSK donated the first 100 million albendazole tablets as part of its commitment to fight lymphatic filariasis. 

GSK marks the 15th anniversary of AZT, the first medicine used to treat HIV/AIDS. 

GSK‘s Positive Action programme celebrates its tenth anniversary. 

By the end of 2002, GSK had secured 120 arrangements to supply preferentially-priced HIV/AIDS medicines to 50 of the world‘s poorest countries.
2003
 
On 27 July 2003, ten million people in Sri Lanka received free doses of GSK-donated albendazole to help prevent the transmission of lymphatic filariasis. 

GSK launches Wellbutrin XL, an anti-depressant medicine, in the US.
2004
 
GSK ships 33 million tablets of preferentially-priced Combivir (HIV treatment) to Africa. 

GSK launches its Clinical Trial Register, an Internet site containing clinical trial data that anyone can access. GSK is the first pharmaceutical company to offer this level of transparency for its clinical trial data.
2005
 
GSK launches Rotarix, a vaccine against rotavirus, a major cause of vomiting and diarrhoea in infants. The launch programme of the product focuses on markets where the need is highest. 

GSK donates medicines and vaccines in response to the Asian Tsunami disaster of December 2004 and devastation caused by Hurricane Katrina in the USA in August 2005. 

GSK announces the FDA approval of Fluarix, an influenza virus vaccine. 

GSK CEO JP Garnier meets US President Bush to discuss pandemic flu planning. 

GSK is highlighted by Bill Gates of the Bill & Melinda Gates Foundation in recognition of the company's commitment to R&D on malaria and other neglected diseases. 

GSK take steps to bolster it leadership position in pandemic flu preparedness by investing in flu vaccine production facilities, the acquisition of vaccines production facilities and the development of candidate pandemic flu vaccines.
2006
 
GSK produces over 10 million packs of its anti-flu treatment Relenza in one year. 

To boost its consumer healthcare portfolio, GSK acquires CNS Inc., producers of the Breathe Right nasal dilator strips and FiberChoice dietary fibre supplements. 

By the end of 2006, 600 million treatments for lymphatic filariasis had been donated as part of the company's commitment to eradicate this disease. 

GSK wins New Business Award for efforts to end lymphatic filariasis. 

Rotarix, the first vaccine against rotavirus is made available in Europe.
2007
 
In a busy year for acquisitions, GSK acquires Domantis, a leader in developing antibody therapies, Praesis Pharmaceuticals, a biopharmaceuticals company and Reliant Pharmaceuticals, a producer of cardiovascular medicines. 

GSK launches alli, over-the-counter orlistat, for first FDA-approved treatment for obesity in the US. 

GSK gains US approval for Tykerb, a new treatment for advanced breast cancer. 

Cervarix, GSK‘s cervical cancer vaccine approved in Europe. 

GSK announces submission of combination vaccine Globorix to the European Medicines Agency (EMEA) with the intention of providing the vaccine to Africa with no commercial reward. 

Andrew Witty named CEO Designate to replace JP Garnier in May 2008 

GSK obtains exclusive US OTC marketing rights to Mevacor (lovastatin) from Merck & Co., Inc. 

New R&D centre opened in China.
2008
 
GSK marks the ten year anniversary of its commitment to eliminate lymphatic filariasis. 

New allergic rhinitis treatment Avamys approved in Europe. 

GSK reduces prices for anti-retrovirals in the world's poorest countries. 

FDA approves Rotarix, a vaccination against rotavirus. 

FDA approves Treximet for the treatment of migraine. 

Andrew Witty succeeds JP Garnier as Chief Executive Officer. 

GSK acquires Sirtris Pharmaceuticals Inc, a world leader in sirtuin research and development. 

FDA approves Requip XL, an oral treatment for Parkinson‘s disease. 

Cervarix, GSK's cervical cancer vaccine, wins tenden for UK national immunisation programme. 

GSK sets out three new strategic priorities: grow a diversified global business; deliver more products of value; simplify the operating model. 

GSK acquires the leading dry mouth brand, Biotene

GSK ceases providing corporate political contributions.
2009
 
Weight loss medicine alli launches in Europe. 

Synflorix, GlaxoSmithKline‘s pneumococcal vaccine, receives European authorisation. 

GSK‘s commitment to emerging markets is strengthened through agreements with Aspen, Dr. Reddy‘s and UCB. 

GSK becomes a leader in skincare with the acquisition of Stiefel

As influenza A (H1N1) spreads across the world, GSK commits to tackling the pandemic with its anti-retroviral and vaccine products. 

GSK and Pfizer launch ViiV Healthcare, a new company focused on delivering advances in treatment and care for HIV communities. 

Agreement reached to launch Lucozade in China. 

GSK‘s H1N1 Pandemrix vaccine receives European Commission Approval. 

Cervarix approved in USA and Japan. 

World‘s largest malaria vaccine trial gets underway in seven African countries. 

GSK signs agreement with the World Health Organization to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries. 

GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed. 

As part of its commitment to greater transparency, GSK publishes speaking and consulting fees paid to US physicians.
2010
 
GSK contributes $1.4 million of medicines to support victims of the Haiti earthquake. 

GSK announces open innovation strategy to help deliver new and better medicines for people living in the world‘s poorest countries. New collaborations will share intellectual property for neglected tropical diseases such as malaria. 

GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. 

GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world‘s poorest countries. 

European approval granted for Duodart

GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix. 

GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine. 

GSK and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases. 

GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China.
2011
 
GSK announces move to new environmentally-friendly building in Philadelphia USA. 

Rapid introduction of Synflorix™ in Kenya at around 90% discount enables vaccination of millions of children against pneumococcal disease. 

Launch of Sensodyne Repair & Protect, the world’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth. 

GSK to reimburse 100% of uncapped tuition fees for all undergraduates it recruits in the UK